Oppenheimer analyst Leland Gershell maintains $Biomarin Pharmaceutical (BMRN.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 37.7% and a total average return of 4.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin delivered a robust financial quarter, with a slight increase in its guidance for both revenue and earnings. The valuation of the company's enzyme replacement therapy business is believed to be equal to or greater than the current trading level of the company's shares. The anticipation for BMN333, which is slated to enter clinical trials in early 2025, is high as it has the potential to be a major factor in maintaining market share in achondroplasia and may expand to additional indications where Voxzogo is under investigation.
BioMarin's quarterly financial outcomes indicated a surpassing of estimated top and bottom lines, with a modest increase in the fiscal 2024 forecast for all principal indicators. Analysts note that although Voxzogo's performance was below expectations, this shortfall was compensated by the stronger than anticipated outcomes from various offerings within the company's enzyme replacement therapy portfolio.
The assessment notes an appealing entry point for BioMarin at the current share value, highlighting the company's solid foundational business and the possibility for significant operating margin growth in the upcoming years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奥本海默控股分析师Leland Gershell维持$拜玛林制药 (BMRN.US)$持有评级。
根据TipRanks数据显示，该分析师近一年总胜率为37.7%，总平均回报率为4.2%。
此外，综合报道，$拜玛林制药 (BMRN.US)$近期主要分析师观点如下：
BioMarin交付了强劲的财务季度，营业收入和盈利指引略微增加。公司酶替代疗法业务的估值被认为等于或高于公司股票目前的交易水平。对于计划于2025年初进入临床试验的BMN333的预期很高，因为它有潜力成为在长骨发育不全维持市场份额的主要因素，可能扩展到Voxzogo正在接受调查的其他适应症。
BioMarin季度财务结果显示超过了预期的主要指标，所有主要指标的财政2024预测略有增加。分析师指出，尽管Voxzogo的表现低于预期，但这一不足得到了公司酶替代疗法组合中各种产品预期之外的更强预期结果的补偿。
评估指出，在当前股价的情况下，BioMarin具有吸引人的入场点，突显了公司坚实的基础业务和未来几年显著的营业利润率增长可能性。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
